Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Boehringer Drug Combination Showed Response at 12 Weeks in Study

Boehringer Ingelheim GmbH said 76 percent of patients taking an interferon-free combination of two experimental drugs with ribavirin had a virological response after 12 weeks in a mid-stage study.

The data from an interim analysis of the Sound-C2 trial, which tested drugs BI201335 and BI207127, was presented today at the American Association for the Study of Liver Disease meeting in San Francisco.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.